Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed CAR-T, has received approval for treating patients with relapsed or refractory multiple myeloma [26]. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.